-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Cytokinetics, Raises Price Target to $105

Benzinga·11/05/2026 22:00:46
Diffusion vocale
Citigroup analyst Eric Joseph maintains Cytokinetics (NASDAQ:CYTK) with a Buy and raises the price target from $99 to $105.